In This Article:
BRAIN Biotech AG (ETR:BNN) just released its latest yearly report and things are not looking great. It was a pretty negative result overall, with revenues of €55m missing analyst predictions by 4.0%. Worse, the business reported a statutory loss of €0.51 per share, much larger than the analysts had forecast prior to the result. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
Check out our latest analysis for BRAIN Biotech
Taking into account the latest results, the consensus forecast from BRAIN Biotech's three analysts is for revenues of €60.7m in 2025. This reflects a solid 9.4% improvement in revenue compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 44% to €0.28. Before this earnings announcement, the analysts had been modelling revenues of €62.5m and losses of €0.17 per share in 2025. While this year's revenue estimates dropped there was also a very substantial increase in loss per share expectations, suggesting the consensus has a bit of a mixed view on the stock.
The average price target was broadly unchanged at €6.64, perhaps implicitly signalling that the weaker earnings outlook is not expected to have a long-term impact on the valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values BRAIN Biotech at €10.00 per share, while the most bearish prices it at €5.10. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We can infer from the latest estimates that forecasts expect a continuation of BRAIN Biotech'shistorical trends, as the 9.4% annualised revenue growth to the end of 2025 is roughly in line with the 9.5% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 4.2% per year. So it's pretty clear that BRAIN Biotech is forecast to grow substantially faster than its industry.